| 摘要 |
The present invention relates to a use of miR-101 as a NLK expression inhibitor and, more specifically, to a novel use of miR-101 which can treat liver cancer by inhibiting NLK expression and cell proliferation of a liver cancer cell line through miR-101 binding to NLK 3′UTR. The present invention first investigates miR-101 is a regulator which inhibits NLK expression, wherein the miR-101 which inhibits NLK expression can be helpfully used in a method for preventing or treating liver cancer induced by NLK overexpression and can be effectively useful in treating other various diseases induced by NLK overexpression. |
